Aptose Biosciences Inc. (NASDAQ:APTO - Get Free Report) (TSE:APS) CEO William G. Rice purchased 100,000 shares of the business's stock in a transaction that occurred on Monday, November 25th. The stock was acquired at an average price of $0.20 per share, for a total transaction of $20,000.00. Following the purchase, the chief executive officer now owns 613,252 shares of the company's stock, valued at approximately $122,650.40. This represents a 19.48 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Aptose Biosciences Stock Performance
Shares of NASDAQ APTO opened at $0.18 on Wednesday. The stock's 50 day moving average price is $0.37 and its two-hundred day moving average price is $0.58. Aptose Biosciences Inc. has a 52-week low of $0.13 and a 52-week high of $2.91.
Analysts Set New Price Targets
APTO has been the topic of several recent analyst reports. HC Wainwright cut their price target on Aptose Biosciences from $7.00 to $2.00 and set a "buy" rating on the stock in a research note on Wednesday, November 20th. StockNews.com initiated coverage on Aptose Biosciences in a research note on Thursday, November 21st. They issued a "hold" rating on the stock.
I was wrong. Dead wrong.
From Porter & Company | Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was.
Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.
Read Our Latest Report on Aptose Biosciences
Institutional Trading of Aptose Biosciences
An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp lifted its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO - Free Report) (TSE:APS) by 71.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 401,750 shares of the biotechnology company's stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 26.62% of the company's stock.
Aptose Biosciences Company Profile
(
Get Free Report)
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
